Fidanacogene elaparvovec

Therapeutic indications

Fidanacogene elaparvovec is indicated for:

Moderate to severe hemophilia B

Population group: only adults (18 - 65 years old)

Fidanacogene elaparvovec is indicated for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fidanacogene elaparvovec is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Vaccinations

Vaccines

Advanced hepatic fibrosis or advanced hepatic cirrhosis

at least one of
Hepatic fibrosis
Cirrhosis of liver

Active infections, either acute or uncontrolled chronic

Infectious disease

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2024: BEQVEZ Solution for infusion
Summary of Product Characteristics (SPC) 2024: BEQVEZ Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈